NCT05609903View on ClinicalTrials.gov

Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

August 1, 2020

Study Completion Date

May 31, 2022

Conditions
Breast Cancer Metastatic
Interventions
DRUG

Atezolizumab in combination with nab-paclitaxel

Treatment of patients with stage IV triple negative breast cancer with Atezolizumab in combination with nab-paclitaxel

Trial Locations (1)

00167

Policlinico A. Gemelli - IRCCS, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT05609903 - Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter